Literature DB >> 27890842

Treatment of a Patient with Abdominal Aortic Aneurysm and Hepatocellular Carcinoma.

Slobodan Cvetkovic1, Igor Koncar1, Daniel Galun2, Jelena Ribac3, Miroslav Markovic1, Nikola Ilic1, Marko Dragas1, Lazar Davidovic1.   

Abstract

BACKGROUND: The surgical tactics in cases of abdominal aortic aneurysms (AAA) and intra-abdominal malignancy are not uniform in the literature and are still a matter of debate. In this case report, we present a patient with coexisting AAA and primary liver cancer managed by simultaneous open AAA repair and liver resection After laparotomy and intraoperative liver ultrasonography that confirmed resectability of the tumor, aneurysm repair was performed with aorto-aortic tube grafting after interrenal cross-clamping Radiofrequency-assisted liver transection was performed to complete an anterior anatomic resection of liver segments VI and VII. The postoperative course was uneventful and the patient was discharged on a postoperative day 10.
METHODS: This was prospective follow up of one patient.
RESULTS: The patient is free from disease at 18-month follow-up.
CONCLUSIONS: The best treatment strategy for patients with AAA and malignant disease is still not clearly defined. Strategy selection is made individually according to the risk of rupture of AAA, general condition of the patient, experience of the teams that should perform the procedure and estimated life expectancy after resection of malignant disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27890842     DOI: 10.1016/j.avsg.2016.07.075

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  1 in total

1.  Management of Concomitant Abdominal Aortic Aneurysm and Intra-abdominal, Retroperitoneal Malignancy.

Authors:  Vladislav Treska; Jiri Molacek; Bohuslav Certik; Karel Houdek; Petr Hosek; Veronika Soukupova; Christiana Stogerova; Aneta Svejdova
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.